secwatch.observer — SEC 8-K summary
======================================

Issuer:     GYRE THERAPEUTICS, INC. (GYRE)
CIK:        0001124105
Form:       8-K/A
Filed at:   2026-04-17T23:59:59+00:00
Accession:  0001140361-26-015307
Event type: m_and_a
Sentiment:  neutral
Materiality: 0.20
Item codes: 1.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Gyre Therapeutics amends 8-K to correct Cullgen stock conversion terms in $300M acquisition
--------------------------------------------------------------------------------

- Amendment fixes clerical error in original March 2, 2026 8-K describing stock conversion for Cullgen holders.
- Designated Cullgen shareholders receive Series B Convertible Preferred, convertible into 5 Gyre common shares each.
- Other Cullgen holders receive Gyre common stock at exchange ratio of 0.4753 per Cullgen share.
- All-stock deal values Cullgen at ~$300 million; no substantive changes to merger agreement beyond correction.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1124105/000114036126015307/0001140361-26-015307-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1124105/000114036126015307/ef20070667_8ka.htm
  HTML page:      https://secwatch.observer/filing/0001140361-26-015307

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer